SPPI News and Press, Spectrum Pharmaceuticals Inc. From 06/04/21

Spectrum Pharmaceuticals ([[SPPI]] -1.0%) announced data from an ongoing Phase 2 study for poziotinib in patients with non-small cell lung cancer with EGFR or HER2 exon 20 mutations.The results from the multi-cohort, multi-center study are available in a poster presentation on the w...

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today presented an e-poster on poziotinib CNS activity in patients with NSCLC with EGFR or HER2 exon 20 mutations. These data from Cohorts 1, 2 and 3 of the ongoing Z...

ASCO is a very important cancer clinical research meeting. We identified 70 smid-cap cancer companies presenting updated clinical data at ASCO21. 13 companies' value increased by over 10% with ASCO21 info release thus far. PDSB is an early ASCO21 mover, with its HPV vaccine ca...

Spectrum Pharmaceuticals (SPPI) announces that the U.S. FDA has initiated a pre-approval inspection for ROLONTIS (eflapegrastim).Shares up more than 3% premarket.ROLONTIS is a novel, long-acting granulocyte colony-stimulating factor ((G-CSF)) seeking an indication for the treatment ...

Vertex Energy (VTNR) +28%.Cloudera CLDR +24% on being acquired by Clayton, Dubilier & Rice and KKR for $5.3 billion.Orbsat Corp Common Stock (OSAT) +19%.AMC Entertainment Holdings AMC +16% on raising $230.0 million.Lineage Cell Therapeutics LCTX +14% on updat...

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced that the U.S. Food and Drug Administration (FDA) is “on site” for the ROLONTIS® (eflapegrastim) manufacturing facility inspection...

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced a poster presentation on poziotinib CNS activity in patients with NSCLC with EGFR or HER2 exon 20 mutations. This poster presentation will be availabl...

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today that management will present an overview of the company's business strategy and development-stage programs at two upcoming virtual investor conference...

Rolontis approval was delayed due to Covid-19 and the FDA's inability to inspect its Korean manufacturing facility. The FDA plans to inspect the Hanmi facility this month. That should be an opportunity for a quick investment. For further details see: Spectrum Pharmaceuti...

Spectrum Pharmaceuticals, Inc. (SPPI) Q1 2021 Earnings Conference Call May 13, 2021 16:30 ET Company Participants Kurt Gustafson - Chief Financial Officer Joe Turgeon - President and Chief Executive Officer Francois Lebel - Chief Medical Officer Conference Call Participants Maury Raycroft - J...